Estrella Immunopharma, Inc. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On August 17, 2026, Estrella Immunopharma received notice of failure to satisfy continued listing standards (Item 3.01). The filing does not specify the dollar amount involved, specific listing rule violated, or remediation timeline. This is a delisting notice, not a completed delisting.
Why this rating
Delisting notice is existential threat for $20.5M public company. Threatens access to capital markets and shareholder value.
Extracted items
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.